Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.56 |
| ▸ | CA6 | P23280 | 5/20 | 0.56 |
| ▸ | CA7 | P43166 | 5/20 | 0.56 |
| ▸ | CA9 | Q16790 | 5/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | CA4 | P22748 | 4/20 | 0.53 |
| ▸ | CA5A | P35218 | 4/20 | 0.53 |
| ▸ | CA3 | P07451 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL9100273 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL9716193 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL1565417 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL18288 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL863599 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL27525013 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL3657736 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL725777 | 0.94 | CA12 (0.56) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL6240702 | 0.94 | CA12 (0.56) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL202712 | 0.94 | CA12 (0.56) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0629617-B2 | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INT BV (NL) | 2007-09-26 | — | — | EP | disclosed |
| EP-1377557-B1 | METHODS OF SYNTHESIZING HETEROATOM-BEARING LIGANDS AND INTERMEDIATE USED THEREFOR | BRACCO INT BV (NL) | 2006-04-05 | — | — | EP | disclosed |
| US-6958141-B2 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO INTERNATIONAL B.V. (NL) | 2005-10-25 | — | — | US | disclosed |
| US-6933391-B2 | Methods of synthesizing heteroatom-bearing ligands and intermediate used therefor | BRACCO INTERNATIONAL B.V. (NL) | 2005-08-23 | — | — | US | disclosed |
| US-20040191174-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO SUISSE SA (CH) | 2004-09-30 | — | — | US | disclosed |
| US-6699458-B2 | CELL MEMBRANE PERMEABILITIES GREATER THAN THAT OF SUCROSE | BRACCO INTERNATIONAL B.V. (NL) | 2004-03-02 | — | — | US | disclosed |
| US-20040010127-A1 | RHENIUM AND TECHNETIUM COMPLEXES CONTAINING A HYPOXIA-LOCALIZING MOIETY | BRACCO SUISSE SA (CH) | 2004-01-15 | — | — | US | disclosed |
| EP-1377557-A1 | METHODS OF SYNTHESIZING HETEROATOM-BEARING LIGANDS AND INTERMEDIATE USED THEREFOR | BRACCO INTERNATIONAL B.V. (NL) | 2004-01-07 | — | — | EP | disclosed |
| US-6660246-B1 | 3,3,9,9-Tetramethyl-4,8-diazaundecane-2,10-dione 2-Hydrazone 10-Oxime; | BRACCO INTERNATIONAL, BV (NL) | 2003-12-09 | — | — | US | disclosed |
| US-20030187275-A1 | Methods of synthesizing heteroatom-bearing ligands and intermediate used therefor | BRACCO SUISSE SA (CH) | 2003-10-02 | — | — | US | disclosed |
| US-5688487-A | Diagnostic imaging methods using rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO INTERNATIONAL B.V. (NL) | 1997-11-18 | — | — | US | disclosed |
| US-5665329-A | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INTERNATIONAL B.V. | 1997-09-09 | — | — | US | disclosed |
| US-5663307-A | Hydrazone containing ligands and metal complexes thereof | BRACCO INTERNATIONAL B.V. | 1997-09-02 | — | — | US | disclosed |
| US-5656254-A | Polyaza heteroatom-bearing ligands and metal complexes thereof for imaging or radiotherapy | BRACCO INTERNATIONAL B.V. | 1997-08-12 | — | — | US | disclosed |
| US-5651954-A | Method of using hydrazone containing ligands and metal complexes thereof | BRACCO INTERNATIONAL B.V. (NL) | 1997-07-29 | — | — | US | disclosed |
| US-5627286-A | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INTERNATIONAL B.V. | 1997-05-06 | — | — | US | disclosed |
| US-5608110-A | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INTERNATIONAL B.V. | 1997-03-04 | — | — | US | disclosed |
| EP-0688313-A1 | LIGANDS AND METAL COMPLEXES THEREOF | BRACCO International B.V. (NL) | 1995-12-27 | — | — | EP | disclosed |
| WO-1995019338-A1 | LIGANDS AND METAL COMPLEXES THEREOF | BRACCO INTERNATIONAL B.V. (NL) | 1995-07-20 | — | — | WO | disclosed |
| EP-0629617-A1 | Heteroatom-bearing ligands and metal complexes thereof | BRACCO International B.V. (NL) | 1994-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040191174-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | HIF1A, HIF1AN, SLC2A8 | CA12 48/4885CA6 102/4885CA7 111/4885 |
| US-20040010127-A1 | RHENIUM AND TECHNETIUM COMPLEXES CONTAINING A HYPOXIA-LOCALIZING MOIETY | HIF1A, HIF1AN, SLC2A8 | CA12 48/4885CA6 102/4885CA7 111/4885 |
| US-20030187275-A1 | Methods of synthesizing heteroatom-bearing ligands and intermediate used therefor | WEE1, WEE2, CKMT1A; CKMT1B | CA12 375/4885CA6 700/4885CA7 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.